ERBB2 and lung carcinoma: Trastuzumab Deruxtecan (T-DXd), targeting HER2, is the world’s first ADCs in lung cancer, lately presenting prominent outcomes with a median progression-free survival (PFS) of 9.9 months and median overall survival (OS) of 19.5 months in the 5.4 mg/kg group of DESTINY-Lung02 (Goto et al., 2023).